Twist Bioscience Stock Rallies As AI Drug Deals Drive Targets Higher

Twist Bioscience Corporation stocks have been trading up by 7.25 percent following upbeat sentiment around its latest synthetic biology advances.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading TWST

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways

Shares of Twist Bioscience (TWST) have surged as the company inks a high-profile data and antibody services agreement with Eli Lilly’s AI/ML drug discovery platform, TuneLab.
Wall Street has chased the move, with Leerink twice lifting its TWST price target, now at $190, while maintaining an Outperform rating on the name.
Guggenheim more than doubled its TWST target to $212, reinforcing a bullish stance ahead of upcoming Q3 earnings in diagnostics and life science tools.
UBS initiated coverage on TWST at Neutral, but with a sizeable $144 target, reflecting long-term growth expectations across life science and diagnostics tools.
Twist Bioscience is steering toward adjusted EBITDA breakeven by Q4 FY26 while positioning TWST as a “picks-and-shovels” supplier for AI drug discovery, anchored by the Lilly TuneLab deal.

Live Update At 12:33:12 EDT: On Monday, October 05, 2026 Twist Bioscience Corporation stock [NASDAQ: TWST] is trending up by 7.25%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

For active traders, TWST is trading like a classic high-growth, high-expectation story. The stock has ripped from $121.66 on 2026/09/10 to $202.32 on 2026/10/05, an aggressive uptrend with only brief pauses. That move reflects how quickly sentiment has shifted around Twist Bioscience once the AI narrative and big-bank targets lined up.

On the daily chart, TWST shows a series of higher lows and powerful trend days, including a spike from $157.72 to $184.03 on 2026/09/24 and continued follow-through into the $190s and now low $200s. Intraday on 2026/10/05, the 5‑minute tape shows tight consolidation between roughly $200 and $203, signaling controlled, orderly buying rather than a blow‑off top.

More Breaking News

Fundamentally, Twist Bioscience is still losing money, with Q3 2026 net income at -$35.1M on $118.4M in revenue and an EBIT margin around -31.8%. But TWST sports a strong 52% gross margin and positive operating cash flow of $1.1M for the quarter, plus a solid current ratio of 2.7 and low leverage. With revenue growing double digits and guidance pointing to adjusted EBITDA breakeven in Q4 FY26, traders are clearly willing to pay a rich price-to-sales multiple for future profitability.

Why Traders Are Watching TWST Right Now

The core of the TWST story today is the Lilly TuneLab agreement. Twist Bioscience will provide antibody characterization data and related wet‑lab services directly into Eli Lilly’s AI/ML platform. That means Lilly’s TuneLab users can order TWST’s antibody services as a built‑in option, turning Twist Bioscience into a default data and services pipeline for AI-driven antibody discovery.

For traders, this is a textbook “picks-and-shovels” setup. TWST is not betting on one blockbuster drug. Instead, Twist Bioscience sells the tools and high‑quality datasets that AI models need, across many programs and partners. That model can support recurring revenue and sticky relationships if Lilly and other pharma names keep ramping AI discovery.

The market reaction backed that up. Multiple headlines flagged how TWST shares jumped several percent on 2026/09/16 after the TuneLab news, with follow‑through days afterward. When a single partnership can push a stock like Twist Bioscience several points in one session, it tells traders this ticker reacts strongly to incremental AI deal flow.

Wall Street has piled on. Leerink first raised its TWST target from $120 to $160, then again to $190 as it gained confidence in conservative revenue assumptions and pharma adoption of the Twist Bioscience platform. Guggenheim went even further, more than doubling its target from $107 to $212 ahead of Q3 earnings. Even UBS, which came in at Neutral, set a $144 target that sits well above older consensus numbers.

There are nuance points traders should track. Twist Bioscience confirmed its AI‑designed mini‑binder work for Anthropic is “probably sort of” already baked into its fiscal 2027 outlook, meaning not every AI headline will be an upside surprise. And CEO Emily Leproust’s roughly $923,000 share sale around late September drew some attention, although she still holds over 613,000 shares, leaving her heavily aligned with longer‑term holders of TWST.

Put together, the Lilly TuneLab deal, rising price targets, and improving margin trajectory make TWST a momentum magnet on both the daily and intraday charts.

Conclusion

Twist Bioscience sits at the crossroads of two hot themes traders care about: synthetic biology and AI. TWST is leaning into that role by embedding its antibody characterization and data services inside Lilly’s TuneLab platform and pitching itself as a core infrastructure player for AI drug discovery. At the same time, Twist Bioscience is backing the story with strong revenue growth, a 52% gross margin, and a roadmap to adjusted EBITDA breakeven by Q4 FY26.

The market has noticed. TWST now trades above $200 after a sharp run from the low $120s in less than a month, with big banks chasing the move higher. Leerink’s Outperform and rising targets, Guggenheim’s $212 call, and UBS’s high Neutral target create a backdrop where any new AI‑related partnership or upside earnings surprise can spark fast moves. For short‑term traders, that translates into volatility and clean technical levels; for swing traders, TWST is shaping up as a trend name as long as the higher‑low structure holds. In a fast‑moving setup like this, many momentum‑focused traders are tempted to buy breakouts blindly, but that’s where process matters. As Tim Bohen, lead trainer with StocksToTrade says, “I never chase price. The best opportunities allow me to enter on my terms, not when I’m feeling pressured.” That mindset is especially relevant when a stock has already had a big run yet continues to attract attention from Wall Street and day traders alike.

At the same time, the stock’s rich price-to-sales ratio, ongoing losses, and insider and institutional ownership changes remind traders not to get complacent. In the words of Tim Sykes, “The market rewards preparation, not prediction — study the pattern, manage the risk, and never fall in love with a story.” With Twist Bioscience, the story is powerful, but disciplined trading around the news and the chart remains the edge.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!